Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto in Hypertensive Heart Disease with LVH
NCT03553810Phase 2Completed
- Sponsor
- National Heart Centre Singapore
- Start
- Apr 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sacubitril + valsartan in hypertensive heart disease (2 arms), sponsored by National Heart Centre Singapore. Primary endpoint: Fibrosis volume at 52 weeks. Started Apr 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertensive heart disease
Beyond the preview
Go deeper on NCT03553810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553810.